GSK inks pact with 23andMe to de­velop novel medicines

BioSpectrum (Asia) - - World News -

GSK and 23andMe have un­veiled an ex­clu­sive four-year col­lab­o­ra­tion that will fo­cus on re­search and de­vel­op­ment of in­no­va­tive new medicines and po­ten­tial cures, us­ing hu­man ge­net­ics as the ba­sis for dis­cov­ery. The col­lab­o­ra­tion will com­bine 23andMe’s large-scale ge­netic re­sources and ad­vanced data sci­ence skills, with the sci­en­tific and med­i­cal knowl­edge and com­mer­cial­i­sa­tion ex­per­tise of GSK. The goal of the col­lab­o­ra­tion is to gather in­sights and dis­cover novel drug tar­gets driv­ing disease pro­gres­sion and de­velop ther­a­pies for se­ri­ous un­met med­i­cal needs based on those dis­cov­er­ies.

All ac­tiv­i­ties within the col­lab­o­ra­tion will ini­tially be co-funded (50-50), with ei­ther com­pany hav­ing cer­tain rights to re­duce its fund­ing share for any col­lab­o­ra­tion pro­gramme. It is ex­pected that this col­lab­o­ra­tion will jointly progress a num­ber of tar­gets per year, with ei­ther com­pany able to in­de­pen­dently progress ad­di­tional tar­gets iden­ti­fied within the col­lab­o­ra­tion. GSK will also have the right to work with 23andMe to an­a­lyse 23andMe’s data­base for val­i­da­tion of GSK’s ex­ist­ing ther­a­peu­tic port­fo­lio as well as lever­age 23andMe’s ca­pa­bil­i­ties for clin­i­cal trial re­cruit­ment. Both GSK and 23andMe will share in the pro­ceeds from new treat­ments and medicines aris­ing from the col­lab­o­ra­tion.

Ad­di­tion­ally, GSK has made a $300 mil­lion eq­uity in­vest­ment in 23andMe. To­gether, GSK and 23andMe will fo­cus on trans­lat­ing ge­netic and phe­no­typic data into R&D ac­tiv­i­ties that will im­prove tar­get se­lec­tion to al­low safer, more ef­fec­tive pre­ci­sion medicines to be dis­cov­ered.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.